FDA approves GSK and Theravance COPD drug

Share this article:

US regulators approved Anoro Ellipta, an inhaled lung drug treatment for use in COPD. The drug—developed in tandem by Glaxo and Theravance—carries a black box warning for an increased risk of asthma-related death. In September, an advisory panel endorsed the drug 11-2. Analysts forecast annual sales of Anoro Ellipta at $2.65 billion by 2018, according to Thomson Reuters.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.